ArticleCureus2026
Tumefactive Multiple Sclerosis Mimicking an Intracranial Mass in a 34-Year-Old Man: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumefactive multiple sclerosis (TMS) is a rare demyelinating variant of multiple sclerosis that can closely mimic intracranial malignancy or abscess on imaging. This case highlights diagnostic complexity when focal neurological deficits occur alongside a concurrent dermatomal rash. A 34-year-old man with no prior neurological history presented with three days of progressive left-sided weakness and numbness, preceded by ipsilateral neck pain and a pruritic vesicular rash, initially treated as herpes zoster. Brain imaging revealed a 3.5 cm right frontal ring-enhancing lesion with surrounding vasogenic edema and minimal mass effect. Cervical spine MRI demonstrated a concurrent enhancing lesion at C2 to C3. Cerebrospinal fluid showed mildly elevated protein and oligoclonal bands, supporting an inflammatory demyelinating process. He was treated with intravenous methylprednisolone (1 g daily for five days) followed by an oral prednisone taper, with complete clinical recovery at four-week follow-up. Brain biopsy was deferred after neurosurgical consultation. Integrating clinical context, MRI patterns, and CSF findings can support early recognition of TMS and help avoid unnecessary antimicrobial therapy or invasive diagnostic procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.